Status:

TERMINATED

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema

Lead Sponsor:

AsclepiX Therapeutics, Inc.

Conditions:

Diabetic Macular Edema (DME)

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This study is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT1...

Detailed Description

Upon providing informed consent, subjects will be sequentially enrolled into the study. Decision regarding dose escalation will be based on the recommendation from the Data Monitoring Committee (DMC)....

Eligibility Criteria

Inclusion

  • Patients 18 years of age or older with diabetic macular edema (DME) diagnosis secondary to diabetes mellitus Type 1 or 2
  • Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 65 to 23 in the study eye
  • Willing and able to comply with clinic visits and study-related procedures
  • Provide signed inform consent

Exclusion

  • Any signs of high risk proliferative diabetic retinopathy in the study
  • Previously-treated patients who are not responders to anti-VEGF
  • Panretinal laser photocoagulation within 6 months and macular laser photocoagulation with 3 months of screening in the study eye
  • Note: Other inclusion/exclusion criteria apply.

Key Trial Info

Start Date :

December 10 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2022

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT04697758

Start Date

December 10 2020

End Date

October 1 2022

Last Update

March 22 2024

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

AsclepiX Investigative Site

Gilbert, Arizona, United States, 85053

2

AsclepiX Investigative Site

Los Angeles, California, United States, 90211

3

AsclepiX Investigative Site

St. Petersburg, Florida, United States, 33711

4

AsclepiX Investigative Site

Boston, Massachusetts, United States, 02114